Cargando…

A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors

Src is overexpressed in various cancers, including 27% of non-small cell lung cancer NSCLC, and is correlated with poor clinical outcomes. We hypothesize that Src kinase inhibitors, including Bosutinib, may exhibit clinical synergy in combination with the antifolate drug pemetrexed. In this Phase I,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karim, Nagla Abdel, Ullah, Asad, Wang, Hongkun, Shoukier, Mahran, Pulliam, Steven, Khaled, Ahmed, Patel, Nikhil, Morris, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776616/ https://www.ncbi.nlm.nih.gov/pubmed/36547158 http://dx.doi.org/10.3390/curroncol29120744

Ejemplares similares

Metastatic Malignant Peripheral Nerve Sheath Tumor (MPNST) in Neurofibromatosis Type 1: Challenges in Diagnosis and Management
por: Pulliam, Steven, et al.
Publicado: (2022)

A Phase I Trial to Determine the Safety and Tolerability of Autophagy Inhibition Using Chloroquine or Hydroxychloroquine in Combination With Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors
por: Karim, Nagla Abdel, et al.
Publicado: (2022)

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M., et al.
Publicado: (2012)

Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?
por: Chiruvella, Varsha, et al.
Publicado: (2022)

Recurrent Metastatic Chordoma to the Liver: A Case Report and Review of the Literature
por: Dickerson, Thomas E., et al.
Publicado: (2022)

Endobronchial lipoma
por: Anbazhakan, Lakshitha, et al.
Publicado: (2022)

Phase I study of pemetrexed with sorafenib in advanced solid tumors
por: Poklepovic, Andrew, et al.
Publicado: (2016)

Prolonged Response of Metastatic Programmed Death-Ligand 1 (PD-L1) Negative Basaloid Squamous Cell Carcinoma of the Lung to Maintenance Immunotherapy
por: Fox, Ashley D, et al.
Publicado: (2022)

Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors
por: Sobash, Philip T., et al.
Publicado: (2022)

The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Sama, Srikar, et al.
Publicado: (2022)

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
por: Isakoff, S J, et al.
Publicado: (2014)

Assessment of Tissue Adequacy by EBUS in Conjunction with PET Scan and Operator’s Experience
por: Karim, Nagla Abdel, et al.
Publicado: (2022)

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

The Unusual Presentation of a Single Case of Synchronous Metastatic Clear Cell Renal Cell Carcinoma to the Gallbladder: A Case Report and Literature Review
por: PATTERSON, GREGORY TAYLOR, et al.
Publicado: (2021)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Effect of Exercise Training on Quality of Life, Symptoms, and Functional Status in Advanced-Stage Lung Cancer Patients: A Systematic Review
por: Nguyen, Tena, et al.
Publicado: (2023)

Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
por: Abdel-Karim, Nagla, et al.
Publicado: (2019)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Pregnancy outcomes in patients treated with bosutinib
por: Cortes, Jorge E, et al.
Publicado: (2020)

A conserved water-mediated hydrogen bond network defines bosutinib’s kinase selectivity
por: Levinson, Nicholas M., et al.
Publicado: (2013)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

Primary Extra-Pleura Leiomyoma: A Case Report and Literature Review
por: Ullah, Asad, et al.
Publicado: (2022)

Incident pulmonary arterial hypertension associated with Bosutinib
por: Yo, Shaun, et al.
Publicado: (2020)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018)

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
por: Hochhaus, Andreas, et al.
Publicado: (2020)

The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases
por: Ozanne, James, et al.
Publicado: (2015)

Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity
por: Moguillansky, Natalia I., et al.
Publicado: (2017)

Bosutinib-Induced Stevens-Johnson Syndrome and Evidence of Tolerance to a Structurally Dissimilar Tyrosine Kinase Inhibitor
por: Avila-Castano, Karol, et al.
Publicado: (2022)

Control of mammary tumor differentiation by SKI-606 (bosutinib)
por: Hebbard, Lionel, et al.
Publicado: (2010)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018)

Bosutinib Inhibits EGFR Activation in Head and Neck Cancer
por: Segrelles, Carmen, et al.
Publicado: (2018)

Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study
por: Zhang, D S, et al.
Publicado: (2015)

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
por: Abumiya, Maiko, et al.
Publicado: (2021)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia
por: Garrett, May, et al.
Publicado: (2023)

Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?
por: Karim, Nagla Abdel, et al.
Publicado: (2022)

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
por: Louvet, C., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1h8nuf8vnqcdregq0rkbsm7p3l